Almost all women with breast cancer have dermatofibromas.
Five women with breast cancer had their dermatofibromas excised and tested for arsenic. A total of 56 women with breast cancer and 56 women without breast cancer were examined for the presence of dermatofibromas.
Dermatofibromas were found to have a lethal amount of arsenic. Either the dermatofibroma was caused by arsenic or became a reservoir to trap arsenic. Women with breast cancer and multiple dermatofibromas (n = 38) had a 100% chance of getting the disease. Women with 1 dermatofibroma (n = 11) had a 60% chance of getting the disease. Women with no dermatofibromas (n = 7) had only a 12% chance of getting the disease. In the group without breast cancer, 47 of 56 patients had no dermatofibromas and none had multiple dermatofibromas. Nine patients had 1 dermatofibroma but, as shown by the Figure, had protection by not following every step (probability).
Dermatofibromas are caused by arsenic and set off a cascade of events leading to breast cancer. Screening women in their 20s, 30s, and 40s for dermatofibromas and removing them should eradicate at least 80% to 90% of breast cancer cases.
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship
The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.